As an example, a combination of introducing the tumor suppressor gene p16/INK4A as gene therapy with anti-JARID1B treatment potentially leads to the efficient induction of a senescence-associated phenotype in esophageal cancer. The gene discussed is CDKN2A; the disease is esophageal cancer.